In 2018, the PARP inhibitors (PARPi) olaparib and talazoparib were approved by the US Food and Drug Administration (FDA) for treatment of patients with human epidermal growth factor receptor 2—negative (HER2−) advanced breast cancer (ABC) harboring a germline BRCA1/2mut (gBRCA1/2mut) and are now available in many countries for the treatment of gBRCA1/2mut HER2− ABC [7,8,9]. Here, BRCA1 is linked to breast carcinoma.